Orthostatic intolerance syndromes after hematopoietic cell transplantation: clinical characteristics and therapeutic interventions in a single-center experience.

Background

Hematopoietic cell transplantation (HCT) is the treatment of choice for several hematologic malignancies. Advances in HCT techniques and post-transplant treatments have improved the survival of these patients considerably [ 1 ]. Long-term survivors, however, are at risk for developing treatment-related complications. HCT survivors have a 0.6 to 5.6-fold increased risk of cardiovascular (CV) diseases (CVD) including coronary artery disease, cerebrovascular disease, and heart failure [ 2 ]. In patients with Hodgkin’s disease that had received mediastinal irradiation, persistent tachycardia and a blunted hemodynamic response to exercise were observed in nearly 1/3 of patients [ 3 ]. General autonomic dysfunction was found in 50–63% of patients with advanced cancer and may be predictive of reduced survival [ 4 ].

Orthostatic intolerance syndromes, which include orthostatic hypotension (OH) and postural tachycardia syndrome (POTS), are a constellation of conditions characterized by the inability to tolerate the upright position as a consequence of structural or functional autonomic nervous system failure, which impairs the CV compensatory mechanisms usually activated after standing [ 5 ]. They are often under recognized or misdiagnosed, and their prevalence is higher than usually thought, both in the general population and in specific diseases. An increased rate of CV events and subclinical CVD have been recently seen in patients with OH compared to general population [ 6 ]. OH has been reported in a considerable number of patients after lung and kidney-pancreas transplants [ 7 , 8 ], although the causes remain unclear. The incidence of OH and POTS after HCT, instead, has not yet been described.

In the current study, we aimed to evaluate the occurrence of OH and POTS in a cohort of patients who were referred to the cardio-oncology clinic for evaluation after HCT for hematologic malignancies to gain insight into clinical features that may be associated with the development of these conditions.

Methods

Study design and definitions

In this retrospective study we included 132 consecutive patients aged 18 years or older who had HCT for a hematologic malignancy at Virginia Commonwealth University Medical Center between March 2011 and July 2018 and were referred to Cardio-oncology clinic for the evaluation before the procedure. The de-identified medical records were reviewed to obtain demographic data and past medical history including underlying hematologic malignancy, date and type of HCT, pre-transplant CV risk factors and CVD. After HCT, the patients were followed by a Cardiologist. Supine, sitting and standing blood pressure (BP) and heart rate (HR) were measured during the visits. BP and HR were measured according to the American Heart Association recommendations [ 9 ]. All subjects were allowed to rest for 10 min, were pain free and allowed to urinate if needed. BP and HR were measured supine first, then 1 min after changing to the sitting position, then 1 min after changing to the standing position, and when possible the subject was maintained standing for up to 10 min with BP and HR measured at 3, 5, 7 and 10 min and the last values measured were used.

OH was defined as a drop in systolic BP ≥20 mmHg and or in diastolic BP ≥10 mmHg within 3 min of active standing [ 10 , 11 ]. POTS was identified by an increase in HR of more than 30 beats per minute within 10 min of active standing, without a drop in BP values [ 10 , 11 ]. All the patients diagnosed with OH or POTS had symptoms of orthostatic intolerance, such as light-headedness, weakness, blurred vision, etc. At least two physicians reviewed patient’s charts to identify those who had developed OH or POTS after HCT. Disagreements on findings were resolved by discussion.

The study was conducted in accordance with the Declaration of Helsinki and approved by the local Institutional Review Board.

Study endpoints

The primary endpoint of this study was to determine the incidence of OH and POTS after HCT. Secondary aims include the identification of clinical factors associated with the development of OH and POTS and the analysis of the treatments started for these conditions.

Statistical analysis

Continuous variables were presented as median and interquartile range, and data were compared using Mann Whitney U test. Categorical values were expressed as absolute and relative frequencies, and data were compared with χ 2 test or Fisher’s test, as appropriate. For the logistic regression analysis, the measure of uncertainty was expressed as an odds ratio (OR) and 95% confidence interval (CI). Treatments received by patients before the transplant were selected as the variables for the logistic regression analysis.

For all statistical analyses, a two-sided p < 0.05 value was considered statistically significant. Statistical analyses were performed with IBM SPSS Statistics for Windows, Version 25.0 (IBM CO., Armonk, NY) and GraphPad Prism, version 8.2 for Windows (GraphPad Software, La Jolla, CA, USA, www.graphpad.com ).

Results

Clinical characteristics of the cohort

Demographic and clinical characteristics of the cohort are summarized in Table 1 . Patients’ median age was 58 (47–63) years, with 66% ( n = 87) of male and 72% ( n = 90) of self-defined Caucasians. Hypertension was the most common CVD before the transplant (71 patients, 54%). Atrial fibrillation and heart failure were observed in 33 (25%) and 28 (21%) subjects, respectively. A significant number of patients were receiving treatment with anti-hypertensive drugs at the time of follow-up with the cardiologist (Table 1 ). Table 1 Characteristics of the overall cohort Patients ( n = 132) Age, years 58 [47–63] Male sex 87 (65.9) Race Black 33 (25.0) White 95 (72.0) Other 4 (3.0) Hematologic diagnosis Multiple myeloma 32 (24.2) Myelodysplastic syndrome 9 (6.8) Myelofibrosis 9 (6.8) Acute myeloid leukemia 27 (20.5) Acute lymphatic leukemia 11 (8.3) Chronic myeloid leukemia 3 (2.3) Chronic lymphatic leukemia 2 (1.5) Hodgkin’s lymphoma 8 (6.1) Non-Hodgkin’s lymphoma 20 (15.2) Aplastic anemia 4 (3.0) Other 7 (5.4) Donor status Related 28 (21.2) Unrelated 55 (41.7) Not applicable 49 (37.1) HCT type Autologous 49 (37.1) Allogenic 83 (62.9) Cardiovascular diseases and risk factors Hypertension 71 (53.8) Smoking 3 (2.3) Diabetes mellitus 20 (15.2) Hypercholesterolemia 35 (26.5) Chronic kidney disease 4 (3.0) CAD 14 (10.3) Heart failure 28 (21.2) Atrial fibrillation 33 (25.0) Pericarditis 6 (4.5) None 25 (18.9) Anti-hypertensive drugs prior to HCT b-blockers 68 (51.5) Calcium-channel blockers 29 (22.0) ACE inhibitors 16 (12.1) ARBs 6 (4.5) Furosemide/Torsemide 21 (15.9) Spironolactone 8 (6.1) None 92 (69.7) Orthostatic Intolerance Syndromes 47 (34.6) Orthostatic hypotension pre-HCT 3 (2.3) Orthostatic hypotension post-HCT 30 (22.7) Tachycardia syndrome 12 (9.1) The data are presented as a number and (%) of all cases or as median and [interquartile range] Abbreviations : ACE Angiotensin-converting enzyme, ARBs Angiotensin II receptor blockers, CAD Coronary artery disease, HCT Hematopoietic cell transplantation

Allogenic transplants constituted 63% ( n = 83) of HCT (Table 1 ). HCT was performed in 34 patients (24%) to treat multiple myeloma, in 27 (21%) for acute myeloid leukemia and in 20 (15%) for non-Hodgkin’s lymphoma. Other less frequent hematologic diagnoses are listed in Table 1 . Before the transplant, 93% of patients ( n = 123) were treated with alkylating agents. Antimetabolites drugs were used in 67% of subjects ( n = 89) and anthracyclines in 43% of cases ( n = 57). Radiotherapy was required in 35 patients (27%). The other class of chemotherapy/immunotherapy drugs used in our cohort are illustrated in Supplemental Fig. 1 and a complete list of agents is provided in the Supplementary Table 1 .

Among the patients who underwent allogenic transplants, 30 (37%) presented graft-versus-host disease (GVHD) at the time of the cardiologic evaluation post-HCT. The GVHD was acute in 24 (80%) cases and chronic in 6 (20%).

Orthostatic intolerance syndromes

The presence of an orthostatic intolerance syndrome was recorded in 45 patients (34%): 12 (9%) had POTS and 33 (25%) had OH. Among them, three subjects had OH before transplant. The median time from HCT to the diagnosis of new onset of OH or POTS was 82 (24–248) days. In the group of patients who developed OH after the HCT, nine had supine hypertension. No significant differences in baseline demographic characteristics were found when comparing patients with and without OH or POTS (Table 2 ), and neither the hematologic diagnosis nor transplant type differed between two groups. The prevalence of CV diseases and risk factors was similar in patients who developed OH or POTS compared to those without dysautonomia, and the percentage of subjects treated with antihypertensive drugs did not differ in the two groups. Table 2 Characteristics of the overall cohort based on the occurrence of orthostatic hypotension or tachycardia syndrome after bone marrow transplant Patients without OH/POTS ( n = 89) Patients with OH/POTS ( n = 47) p Age, years 58 [49–63] 55 [44–63] 0.26 Male sex 57 (63.3) 30 (71.4) 0.43 Race Black 24 (26.7) 9 (21.4) 0.15 White 64 (72.2) 30 (71.4) Other 1 (1.1) 3 (7.1) Hematologic diagnosis Multiple myeloma 22 (24.4) 10 (23.8) 0.40 Myelodysplastic syndrome 7 (7.8) 2 (4.8) Myelofibrosis 7 (7.8) 2 (4.8) Acute myeloid leukemia 19 (21.1) 8 (19.0) Acute lymphatic leukemia 6 (6.7) 5 (11.9) Chronic myeloid leukemia 2 (2.2) 1 (2.4) Chronic lymphatic leukemia 2 (2.2) 0 Hodgkin’s lymphoma 5 (5.6) 3 (7.1) Non-Hodgkin’s lymphoma 12 (13.3) 8 (19.0) Aplastic anemia 4 (4.4) 0 Other 4 (4.4) 3 (7.2) Donor status Related 19 (21.1) 9 (21.4) 0.83 Unrelated 39 (43.3) 16 (38.1) BMT type Autologous 32 (35.6) 17 (40.5) 0.7 Allogenic 58 (64.4) 25 (59.5) CV diseases and risk factors Hypertension 53 (58.9) 18 (42.9) 0.1 CAD 11 (12.2) 3 (7.1) 0.55 Heart failure 22 (24.4) 6 (14.3) 0.25 Diabetes mellitus 16 (17.8) 4 (9.5) 0.30 Hypercholesterolemia 25 (27.8) 10 (23.8) 0.68 Atrial fibrillation 25 (27.8) 8 (19.0) 0.39 Chronic kidney disease 2 (2.2) 2 (4.8) 0.59 Smoking 2 (2.2) 1 (2.4) 1.00 Pericarditis 4 (4.4) 2 (4.8) 1.00 Treatment with anti-hypertensive drugs prior to BMT b-adrenergic blockers 46 (51.1) 22 (52.4) 1.00 Calcium-channel blockers 21 (23.3) 8 (19.0) 0.66 ACE inhibitors 14 (15.6) 2 (4.8) 0.09 ARBs 4 (4.4) 2 (4.8) 1.00 Furosemide/Torsemide 18 (20.0) 3 (7.1) 0.08 Spironolactone 5 (5.6) 3 (7.1) 0.71 None 24 (27%) 16 (38) 0.22 Number of anti-hypertensive drugs prior to BMT 1 37 (41.1) 14 (33.3) 0.39 2 17 (18.9) 10 (23.8) 3 11 (12.2) 2 (4.8) 4 1 (1.1) 1 (1.1) The data are presented as a number and (%) of all cases or as median and [interquartile range]. P -values were calculated by Kruskall Wallis or Fisher’s exact test or χ 2 test, as appropriate. Statistical significant values are presented in bold character Abbreviations : ACE Angiotensin-converting enzyme, ARBs Angiotensin II receptors blockers, CAD Coronary artery disease, CV Cardiovascular, HCT Hematopoietic cell transplantation, OH Orthostatic hypotension, POTS Postural orthostatic tachycardia syndrome

The characteristic of patients who developed OH or POTS are summarized in Table 3 . The median age was 57 (47–65) years in patients with OH and 50 (39–58) in those with POTS. Male sex and white race were prevalent in both groups. In a subgroup of patients ( n = 16) with OH/POTS only semi-quantitative descriptions were available >20 mmHg drop with standing” or “>30 beats per minute increase with standing”.) The BP values in clinostatism were available for 19 patients in the group diagnosed with OH. The systolic BP dropped from supine to standing position (128 [117–150] vs 92 [83–99], P < 0.001) as well as the diastolic BP (80 [74–90] vs 61 [57–64], P < 0.001) (Fig. 1 ). HR values in clinostatism were available for 7 patients in the subgroup diagnosed with POTS and a significant increased from supine to standing position was observed (84 [72–92] vs 115 [104–126], P = 0.01) (Fig. 2 ). Factors that would predict OH rather than POTS could not be identified (Table 3 ). Table 3 Characteristics of patients who developed orthostatic hypotension or postural tachycardia syndrome after HCT Patients with OH ( n = 30) Patients with POTS ( n = 12) P -value Age, years 57 [47–65] 50 [39–58] 0.1 Male sex 20 (66.7) 10 (83.3) 0.45 Race African-American 8 (26.7) 1 (8.3) 0.43 White 20 (66.7) 10 (83.3) Other 2 (6.7) 1 (8.3) Hematologic diagnosis Multiple myeloma 6 (20.0) 4 (33.3) 0.67 Myelodysplastic syndrome 1 (3.3) 1 (8.3) Myelofibrosis 1 (3.3) 1 (8.3) Acute myeloid leukemia 5 (16.7) 3 (25.0) Acute lymphatic leukemia 4 (13.3) 1 (8.3) Chronic myeloid leukemia 1 (3.3) 0 Chronic lymphatic leukemia 0 0 Hodgkin’s lymphoma 3 (10.0) 0 Non-Hodgkin’s lymphoma 6 (20.0) 2 (16.7) Aplastic anemia 0 0 Other 3 (9.9) 0 Donor status Related 7 (23.3) 2 (16.7) 0.61 Unrelated 10 (33.3) 6 (50.0) BMT type Autologous 13 (43.3) 4 (33.3) 0.73 Allogenic 17 (56.7) 8 (66.7) CV diseases and risk factors Hypertension 12 (40.0) 6 (50.0) 0.73 CAD 1 (3.3) 2 (16.7) 0.19 Heart failure 5 (16.7) 1 (8.3) 0.66 Diabetes mellitus 1 (3.3) 3 (25.0) 0.06 Hypercholesterolemia 5 (16.7) 5 (41.7) 0.12 Atrial fibrillation 5 (16.7) 3 (25.0) 0.69 Chronic kidney disease 1 (3.3) 1 (8.3) 0.5 Smoking 0 1 (8.3) 0.27 Pericarditis 1 (3.3) 1 (8.3) 0.5 Previous treatment with anti-hypertensive drugs b-blockers 14 (46.7) 8 (66.7) 0.32 Calcium-channel blockers 5 (16.7) 3 (25.0) 0.67 ACE inhibitors 1 (3.3) 1 (8.3) 0.5 ARBs 1 (3.3) 1 (8.3) 0.5 Furosemide/Torsemide 2 (6.7) 1 (8.3) 1.00 Spironolactone 1 (3.3) 2 (16.7) 0.19 None 14 (46.7) 2 (16.7) 0.09 Number of anti-hypertensive drugs 1 9 (30.0) 5 (41.7) 0.1 2 6 (20.0) 4 (33.3) 3 1 (3.3) 1 (8.3) 4 1 (3.3) 0 The data are presented as a number and (%) of all cases or as median and [interquartile range] Abbreviations : ACE Angiotensin-converting enzyme, ARBs Angiotensin II receptors blockers, CAD Coronary artery disease, CV Cardiovascular, HCT Hematopoietic cell transplantation, OH Orthostatic hypotension, POTS Postural orthostatic tachycardia syndrome Fig. 1 Differences of SBP and DBP from supine to standing position in patients with orthostatic hypotension at the time of the cardiologic visit. Boxplot showing the SBP and DBP values in the supine and in the standing position. Data are showed as minimum to maximum with the midline representing the median. ** p < 0.001 Fig. 2 Differences of HR from supine to standing position in patients with postural orthostatic tachycardia syndrome at the time of the cardiologic visit. Boxplot showing the HR values in the supine and in the standing position. Data are showed as minimum to maximum with the midline representing the median. ** p < 0.001

In a logistic regression model, radiotherapy was associated with a significant risk of OH or POTS development after HCT (OR 2.682, CI 95% 1.200–5.996, p -value 0.02) (Table 4 ). Treatment with specific antineoplastic medications was also found to be associated with OH or POTS occurrence: anthracyclines (OR 2.303, CI 95% 1.092–4.859, p-value 0.03), corticosteroids (OR 2.364, CI 95% 1.104–5.060, p-value 0.03), anti-microtubules drugs (OR 2.891, CI 95% 1.319–6.339, p-value 0.008), and epipodophyllotoxin (OR 2.850, CI 95% 1.299–6.251, p-value < 0.01) (Table 4 ). When these treatments were included in a multivariate logistic regression model, however, none of them maintained statistical significance. Table 4 Logistic regression analysis showing the association between therapy and OH or POTS at univariate and multivariate analysis Univariate model Multivariate model OR 95% CI P -value OR 95% CI P -value Radiotherapy 2.68 1.20–6.0 0.02 1.92 0.8–4.61 0.15 Anthracyclines 2.30 1.09–4.86 0.03 1.26 0.45–3.52 0.66 Corticosteroids 2.36 1.10–5.06 0.03 1.5 0.62–3.6 0.37 Anti-microtubules 2.89 1.32–6.34 0.01 1.15 0.32–4.12 0.83 Epipodophyllotoxin 2.85 1.3–6.25 0.01 1.90 0.71–5.1 0.20 Angiogenesis inhibitor 0.9 0.37–2.17 0.81 Histone-deacetylase inhibitors 0.42 0.05–3.67 0.43 Kinase inhibitors 1.09 0.40–2.93 0.87 Antimetabolites 0.95 0.44–2.07 0.9 Antitumor antibiotics 1.89 0.54–6.59 0.32 Proteasome inhibitors 0.87 0.38–1.99 0.75 Anti-thymocyte globulin 0.72 0.34–1.52 0.39 Alkylating agents 0.93 0.22–3.91 0.92 Statistically significant p values are displayed in bold characters CI Confidence interval, OH Orthostatic hypotension, POTS Postural orthostatic tachycardia syndrome

Treatment for orthostatic hypotension and postural orthostatic tachycardia syndrome

All patients diagnosed with OH or POTS received education on non-pharmacological treatments which include: 1) avoidance of triggering situations (such as prolonged standing motionless and recumbency, sudden changes in posture, consumptions of alcohol and large meals); 2) elastic stockings; 3) maintenance of adequate hydration and salt intake; 4) exercise. Pharmacological therapy was prescribed in patient with persistent symptoms despite the adoption of these behavioral modifications ( n = 38, 91%)(Fig. 3 A). In the group of 12 patients with POTS, a b-adrenergic blocker was prescribed to 9 (75%) patients, metoprolol in 5 (42%) cases, carvedilol in 4 (33%) and propranolol in 1 (8%). In the group of 30 patients with OH, 24 (80%) subjects received midodrine, 15 (50%) a b-blocker and 7 (23%) fludrocortisone (Fig. 3 A). Of these, 16 (51%) patients were treated with only 1 drug, b-adrenergic blocker in 6 (20%) and midodrine in 10 (33%). A combination of a b-adrenergic blocker and midodrine was used in 8 (27%) patients, and 4 (13%) patients were treated with midodrine and fludrocortisone, 1 (3%) patient received a b-adrenergic blocker in association with fludrocortisone, and 2 (7%) required a combination of a b-adrenergic blocker, midodrine and fludrocortisone to treat the symptoms of OH (Fig. 3 B). Fig. 3 A Pharmacological therapies in patients who developed OH and POTS after HTC. The column graphic represents the percentage of patients treated with different classes of drugs. B Combination of pharmacological treatments in patients who developed OH after HCT. The pie chart represents the percentage of patients treated with different combinations of drugs HTC: hematopoietic cell transplantation; OH: orthostatic hypotension; POTS: postural orthostatic tachycardia syndrome.

All patients described a favorable response to treatment: 17 (45%) patients had resolution of symptoms on monotherapy, the remaining 18 (55%) patients required 2 or more therapies. Of those with OH, midodrine was used as first-line therapy in 26 (87%) patients, and fludrocortisone was added in 8 (27%) cases, hydrocortisone in 1 (3%), and β-adrenergic blockers in 5 (17%) cases. Treatment was interrupted after a median duration of 120 (33–333) days in 21 (60%) of cases.

Discussion

Orthostatic intolerance syndromes, such as OH and POTS, affect both the general population and patients with specific diseases, including those who have received organ transplants [ 7 , 8 , 12 ]. Orthostatic intolerance syndromes are associated with an increased risk of CVD and higher mortality [ 6 , 12 ] and with a diminished quality of life, emphasizing the need for better recognition. In the recent years, autonomic dysfunction has become a recognized CV disorder affecting patients with cancer and cancer survivors more than healthy controls [ 13 ].

In the current study, we described for the first time the prevalence of OH and POTS in patients referred to the cardio-oncology clinic following HCT for several hematologic disorders. OH occurred in 23% of patients and POTS in 9% after HCT. In this cohort of patients, the development of OH or POTS was not associated with the risk factors previously described in other populations, such as age, sex, and the use of anti-hypertensive drugs. While radiotherapy and the use of specific antineoplastic regimens may be risk factors for the development of OH and POTS, the occurrence of these syndromes is more likely associated with the transplant procedure by itself, considering that patients had not been diagnosed with these prior to HCT and none of these risk factors were significant in the multivariate analysis.

Prevalence of OH similar to that found in our population has been previously described by Schuurmans et al. in a small group of lung transplant recipients [ 8 ]. In another recent study, OH occurred in 28% of kidney-pancreas transplant patients [ 7 ]. History of peripheral neuropathy related to long-standing diabetes, was not correlated with the development of OH in this group of patients [ 7 ]. Hyperinsulinemia after transplant and vasodilator neuropeptides released from the pancreas were described as possible responsible agents for OH development, but the biological cause remains unclear.

Berger et al. reported a higher presence of dysautonomia in a group of childhood cancer survivors compared with healthy matched controls [ 14 ]. No differences in factors possibly causing dysautonomia were found between the two groups, but authors were not able to examine a possible association with cancer treatment due to the small sample size [ 14 ]. Recently, in a study by Deuring et al., cardiac autonomic function was measured in a group of HCT survivors of and in healthy matched controls, by the assessment of HR and respiratory sinus arrhythmia (RSA) [ 15 ]. Transplant recipients showed a higher HR and lower RSA compared to control group, indicating the presence of cardiac autonomic dysfunction [ 15 ].

In the general population the incidence of OH exponentially increase with the age, not unexpectedly as some of the risk factors associated with OH development, such as neuropathy, diabetes mellitus, heart disease, Parkinson’s disease, and need of polytherapy are more frequent in the elderly [ 16 , 17 ]. POTS is also commonly diagnosed in adolescents, particularly within two years from the beginning of puberty, but often more benign in its course and often self-limiting [ 18 ]. POTS is two to three times more frequent in female adolescents compared to male and almost 90% of adults patients with POTS are female [ 18 ], with not showing a clear preference for the female sex in older adults. In our cohort we observed higher incidence of POTS and OH in males versus females. This was unexpected and not easily explained. Additional studies are needed to explore this apparent sex-based difference.

Treatments with antihypertensive agents is a well-recognized risk factor for OH and POTS [ 19 ]. In this retrospective analysis, we have not found statistically significant difference in age, sex, use of antihypertensive drugs, between patients with and without OH or POTS. We observed an association between radiotherapy and some classes of chemotherapeutic agents and the development of dysautonomia. However, none of these treatments maintained the statistical significance in the multivariate model, suggesting that other, yet unidentified, factors may contribute to OH and POTS incidence after transplant. Moreover, patients with hematologic malignancy are often treated with several chemotherapy drugs before the HCT, thus complicating the evaluation of the effect of the single agent. A previous study on breast cancer patients highlighted the association between cardiac autonomic dysfunction and anthracyclines [ 20 ], supporting a potential role of this class of drugs in OH and POTS development. Head and neck radiotherapy has been associated with a reduction of BP values after the treatment, but no OH has been recorded [ 21 ]. In another cohort of 282 cancer survivors referred to a cardio-oncology program, 22 subjects were diagnosed with autonomic dysfunction [ 22 ]. Of these, the majority had hematologic disorders and one third had undergone HCT [ 22 ]. The subjects showed impairment in multiple components of the autonomic function (sudomotor, adrenergic and cardiovagal) [ 22 ] [ 22 ]..

Given the timely association with HCT, it is possible that the HCT itself is the leading cause of OH and POTS in this group of patients. Indeed, the transplant lead to an important burden of inflammation, which may be the trigger for OH and POTS development [ 23 ]. The median time from HCT to diagnosis of OH or POTS was 82 (24–248) days. Further studies are required to better investigate the causes of OH and POTS after HCT.

OH is associated with diurnal BP variability and, often, with supine hypertension, which both contribute to intermittent increase in afterload, favoring the development of end-organ damage [ 5 ]. This observation was confirmed also in our cohort, in which 1/3 of patients who developed OH after the HCT presented also supine hypertension.

The management of OH and POTS is mainly driven by symptoms and non-pharmacological treatments are usually considered as first line therapy [ 5 , 24 ]. The non-pharmacological treatments alone can be, however, insufficient in severe cases. One of the limitations of this analysis is the inability to capture the use of non-pharmacological treatments in terms of prescriptions and compliance. The majority (91%) of patients in our cohort required drug prescriptions for OH and POTS. Midodrine, a selective and direct a1-adrenoreceptor agonist, has shown to be effective in reduce symptoms and improve quality of life [ 25 ]. Fludrocortisone is an effective volume expander, but its use is contraindicated in patients with heart failure, kidney failure or supine hypertension [ 26 ]. In POTS, β-adrenergic blockers have been reported to improve symptoms [ 27 , 28 ]. None of these treatments have however been proven to be superior compared to others in reducing outcomes and none of these treatments have been specifically studied in patients after HCT. In our experience midodrine was the most commonly used pharmacologic agent for OH, with fludrocortisone being added in non-responders, and β-adrenergic blockers being used in both patients with OH and POTS. The median duration of treatment was median duration of 120, although a third of patients remained on treatment long-term.

HCT survivors are at risk for several acute and chronic CV complications [ 29 , 30 ]. OH and POTS, however, are rarely considered to be part of these possible adverse consequences, and patients may be not actively screened for this complication after transplant, therefore the exact incidence of these complications in unselected HCT recipients is unknown. OH and POTS can be debilitating, worsen the quality of life of the patients, and may delay the recovery following transplantation [ 31 ]. Several observations have linked OH to negative CV outcomes [ 32 ] and a recent meta-analysis confirmed the association between OH and the risk of all cause-death, coronary heart disease, heart failure and stroke [ 33 ].

Our results are particularly interesting because we describe for the first time the prevalence of OH and POTS in patients referred to cardio-oncology after HCT. The diagnosis of OH and POTS have been made by a cardiologist expert in the cardio-oncology field and confirmed with a careful chart review. Some limitations should be acknowledged. First, this is a retrospective study with obvious potential selection bias toward inclusion of patients with symptoms and/or at perceived cardiovascular risk, therefore limiting our ability to apply these findings to unselected HCT recipients. Second, the lack of a systematic assessment of vital signs may have led to inaccuracies in the detection of OH/POTS and calls for future prospective studies. Third, it is a single-center study, although conducted in a large hospital serving a diverse groups of patients. Finally, the limited number of cases did not allow us to evaluate the possible greater benefit of a treatment compared to the others.

Conclusion

Orthostatic intolerance syndromes are commonly diagnosed in patients referred to the cardiologist after HCT, involving approximately 1/3 of patients and requiring pharmacological therapy to cope with symptoms in the majority of cases. Risk factors specific to this population have been identified but cannot fully explain the incidence of POTS and OH after HCT. Additional research is needed to define the actual incidence of OH and POTS after HCT, identify risk factors, and determine the most effective therapeutic strategy.

Supplementary Information

Additional file 1: Supplemental Figure 1 . Antineoplastic treatment before transplant. Supplementary Table 1 . Chemotherapy/immunotherapy agents used in the overall cohort.

Abbreviations

Blood pressure

Confidence interval

Cardiovascular

Cardiovascular diseases

Hematopoietic cell transplantation

Heart rate

Orthostatic hypotension

Odds ratio

Postural tachycardia syndrome

Michael Hess is deceased.

This paper is dedicated to the memory of Dr. Michael Hess, VCU Health cardio-oncology founder who died in Richmond, VA, on April 13, 2019.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Acknowledgements

none.

Authors’ contributions

AV, GT, EB and UP performed the chart review. AV and GT analyzed data and wrote the manuscript. AA gave suggestions during the writing of the manuscript. AB, JMC, DC, DK, DE, RM, AT critically revised the manuscript. All authors approved the final version of the manuscript.

AV and AA are the guarantors of this work and, as such, have full access to all data in the study and take responsibility for the integrity of data and the accuracy of data analysis.

Authors’ information

Alessandra Vecchié, MD: Pauley Heart Center, Virginia Commonwealth University, Richmond, VA, USA; Department of Internal Medicine, Ospedale di Circolo e Fondazione Macchi, ASST Sette Laghi, Varese Georgia Thomas, MD, PhD: Pauley Heart Center, Virginia Commonwealth University, Richmond, VA, USA Edoardo Bressi, MD: Pauley Heart Center, Virginia Commonwealth University, Richmond, VA, USA Aldo Bonaventura, MD: Pauley Heart Center, Virginia Commonwealth University, Richmond, VA, USA; Department of Internal Medicine, Ospedale di Circolo e Fondazione Macchi, ASST Sette Laghi, Varese; First Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, 6 viale Benedetto XV, 16132 Genoa, Italy. Justin M. Canada, PhD: Pauley Heart Center, Virginia Commonwealth University, Richmond, VA, USA David Chuquin, MD: Pauley Heart Center, Virginia Commonwealth University, Richmond, VA, USA Dinesh Kadariya, MD: Pauley Heart Center, Virginia Commonwealth University, Richmond, VA, USA Usman Piracha, MD1: Pauley Heart Center, Virginia Commonwealth University, Richmond, VA, USA Delia Endicott, NP: Pauley Heart Center, Virginia Commonwealth University, Richmond, VA, USA Roshanak Markley, MD: Pauley Heart Center, Virginia Commonwealth University, Richmond, VA, USA Amir Toor, MD: Massey Cancer Center, Virginia Commonwealth University Antonio Abbate, MD, PhD: Pauley Heart Center, Virginia Commonwealth University, Richmond, VA, USA

Funding

None.

Availability of data and materials

The datasets analyzed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate

Data were collected as part of clinical care and retrospectively collected. The study was approved by Virginia Commonwealth University Institutional Review Board.

Consent for publication

The study was completed under waiver of informed consent.

Competing interests

None.

References

1. Nivison-Smith I Simpson JM Dodds AJ Ma DD Szer J Bradstock KF Relative survival of long-term hematopoietic cell transplant recipients approaches general population rates Biol Blood Marrow Transplant 2009 15 10 1323 1330 10.1016/j.bbmt.2009.06.014 19747641

2. Scott JM Armenian S Giralt S Moslehi J Wang T Jones LW Cardiovascular disease following hematopoietic stem cell transplantation: pathogenesis, detection, and the cardioprotective role of aerobic training Crit Rev Oncol Hematol 2016 98 222 234 10.1016/j.critrevonc.2015.11.007 26643524 PMC5003053

3. Adams MJ Lipsitz SR Colan SD Tarbell NJ Treves ST Diller L Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy J Clin Oncol 2004 22 15 3139 3148 10.1200/JCO.2004.09.109 15284266

4. Fadul N Strasser F Palmer JL Yusuf SW Guo Y Li Z The association between autonomic dysfunction and survival in male patients with advanced cancer: a preliminary report J Pain Symptom Manag 2010 39 2 283 290 10.1016/j.jpainsymman.2009.06.014 20152590

5. Ricci F De Caterina R Fedorowski A Orthostatic hypotension: epidemiology, prognosis, and treatment J Am Coll Cardiol 2015 66 7 848 860 10.1016/j.jacc.2015.06.1084 26271068

6. Juraschek SP, Daya N, Appel LJ, Miller ER 3rd, McEvoy JW, Matsushita K, et al. Orthostatic hypotension and risk of clinical and subclinical cardiovascular disease in middle-aged adults. J Am Heart Assoc. 2018;7(10):e008884. 10.1161/JAHA.118.008884 PMC6015335 29735525

7. Khurana A McCuskey CF Slavcheva EG Orthostatic hypotension in kidney pancreas transplant patients and its relation to preexisting autonomic neuropathy Exp Clin Transplant 2008 6 2 127 131 18816239

8. Schuurmans M Wild J Pazhenkottil A Inci I Kohler M Benden C Orthostatic hypotension appears to be common among lung transplant recipients CHEST 2014 145 3 633A 10.1378/chest.1836513

9. Muntner P Shimbo D Carey RM Charleston JB Gaillard T Misra S Measurement of blood pressure in humans: a scientific statement from the American Heart Association Hypertension 2019 73 5 e35 e66 10.1161/HYP.0000000000000087 30827125 PMC11409525

10. Freeman R Wieling W Axelrod FB Benditt DG Benarroch E Biaggioni I Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome Clin Auton Res 2011 21 2 69 72 10.1007/s10286-011-0119-5 21431947

11. Shen WK Sheldon RS Benditt DG Cohen MI Forman DE Goldberger ZD 2017 ACC/AHA/HRS guideline for the evaluation and Management of Patients with syncope: executive summary: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Rhythm Society Circulation 2017 136 5 e25 e59 28280232 10.1161/CIR.0000000000000498

12. Rose KM Tyroler HA Nardo CJ Arnett DK Light KC Rosamond W Orthostatic hypotension and the incidence of coronary heart disease: the atherosclerosis risk in communities study Am J Hypertens 2000 13 6 Pt 1 571 578 10.1016/S0895-7061(99)00257-5 10912737

13. Fradley MG Beckie TM Brown SA Cheng RK Dent SF Nohria A Recognition, prevention, and Management of Arrhythmias and Autonomic Disorders in cardio-oncology: a scientific statement from the American Heart Association Circulation 2021 144 3 e41 e55 10.1161/CIR.0000000000000986 34134525 PMC8992663

14. Berger C Casagranda L Pichot V Trombert-Paviot B Faure-Conter C Freycon C Dysautonomia in childhood cancer survivors: a widely underestimated risk J Adolesc Young Adult Oncol 2019 8 1 9 17 10.1089/jayao.2018.0021 30136876

15. Deuring G Kiss A Halter JP Passweg JR Grossman P Cardiac autonomic functioning is impaired among allogeneic hematopoietic stem cell transplantation survivors: a controlled study Bone Marrow Transplant 2017 52 1 66 72 10.1038/bmt.2016.176 27376446

16. Finucane C O'Connell MD Fan CW Savva GM Soraghan CJ Nolan H Age-related normative changes in phasic orthostatic blood pressure in a large population study: findings from the Irish longitudinal study on ageing (TILDA) Circulation 2014 130 20 1780 1789 10.1161/CIRCULATIONAHA.114.009831 25278101

17. Fleg JL Evans GW Margolis KL Barzilay J Basile JN Bigger JT Orthostatic hypotension in the ACCORD (action to control cardiovascular risk in diabetes) blood pressure trial: prevalence, incidence, and prognostic significance Hypertension 2016 68 4 888 895 10.1161/HYPERTENSIONAHA.116.07474 27504006 PMC5016241

18. Kizilbash SJ Ahrens SP Bruce BK Chelimsky G Driscoll SW Harbeck-Weber C Adolescent fatigue, POTS, and recovery: a guide for clinicians Curr Probl Pediatr Adolesc Health Care 2014 44 5 108 133 10.1016/j.cppeds.2013.12.014 24819031 PMC5819886

19. Press Y Punchik B Freud T Orthostatic hypotension and drug therapy in patients at an outpatient comprehensive geriatric assessment unit J Hypertens 2016 34 2 351 358 10.1097/HJH.0000000000000781 26599221

20. Viniegra M Marchetti M Losso M Navigante A Litovska S Senderowicz A Cardiovascular autonomic function in anthracycline-treated breast cancer patients Cancer Chemother Pharmacol 1990 26 3 227 231 10.1007/BF02897205 2357771

21. Leibowitz A Grossman E Berkovitch A Levartovski M Appel S Sharabi Y The effect of head and neck radiotherapy on blood pressure and orthostatic hypotension in patients with head and neck tumors Am J Hypertens 2018 31 2 235 239 10.1093/ajh/hpx158 28985342

22. Noor B Akhavan S Leuchter M Yang EH Ajijola OA Quantitative assessment of cardiovascular autonomic impairment in cancer survivors: a single center case series Cardiooncology 2020 6 11 32742722 10.1186/s40959-020-00065-9 PMC7388471

23. Sjøqvist C Snarski E Inflammatory markers in patients after hematopoietic stem cell transplantation Arch Immunol Ther Exp 2013 61 4 301 307 10.1007/s00005-013-0228-z 23563864

24. Sheldon RS Grubb BP 2nd Olshansky B Shen WK Calkins H Brignole M 2015 heart rhythm society expert consensus statement on the diagnosis and treatment of postural tachycardia syndrome, inappropriate sinus tachycardia, and vasovagal syncope Heart Rhythm 2015 12 6 e41 e63 10.1016/j.hrthm.2015.03.029 25980576 PMC5267948

25. Izcovich A Gonzalez Malla C Manzotti M Catalano HN Guyatt G Midodrine for orthostatic hypotension and recurrent reflex syncope: a systematic review Neurology 2014 83 13 1170 1177 10.1212/WNL.0000000000000815 25150287

26. Rowe PC Calkins H DeBusk K McKenzie R Anand R Sharma G Fludrocortisone acetate to treat neurally mediated hypotension in chronic fatigue syndrome: a randomized controlled trial JAMA 2001 285 1 52 59 10.1001/jama.285.1.52 11150109

27. Raj SR Black BK Biaggioni I Paranjape SY Ramirez M Dupont WD Propranolol decreases tachycardia and improves symptoms in the postural tachycardia syndrome: less is more Circulation 2009 120 9 725 734 10.1161/CIRCULATIONAHA.108.846501 19687359 PMC2758650

28. Nogues M Delorme R Saadia D Heidel K Benarroch E Postural tachycardia syndrome in syringomyelia: response to fludrocortisone and beta-blockers Clin Auton Res 2001 11 4 265 267 10.1007/BF02298959 11710800

29. Blaes A Konety S Hurley P Cardiovascular complications of hematopoietic stem cell transplantation Curr Treat Options Cardiovasc Med 2016 18 4 25 10.1007/s11936-016-0447-9 26909819 PMC4766226

30. Aladag E, Demiroglu H, Buyukasik Y, Karakulak UN, Tekin F, Aksu S, et al. Cardiac adverse events during stem cell transplantation for hematological malignancies: a single Centre experience. Transfus Apher Sci. 2020;59(2):102653. 10.1016/j.transci.2019.09.006 32088113

31. Pederson CL Brook JB Health-related quality of life and suicide risk in postural tachycardia syndrome Clin Auton Res 2017 27 2 75 81 10.1007/s10286-017-0399-5 28168561

32. Fedorowski A Ricci F Sutton R Orthostatic hypotension and cardiovascular risk Kardiol Pol 2019 77 11 1020 1027 10.33963/KP.15055 31713533

33. Ricci F Fedorowski A Radico F Romanello M Tatasciore A Di Nicola M Cardiovascular morbidity and mortality related to orthostatic hypotension: a meta-analysis of prospective observational studies Eur Heart J 2015 36 25 1609 1617 10.1093/eurheartj/ehv093 25852216